Sylvia De Brakeleer - Concepedia

Author

Sylvia De Brakeleer

Also Known As

Bernd Frank, Brakeleer, Sylvia De, S De Brakeleer, S. De Brakeleer, S. de Brakeleer, SYLVIA DE BRAKELEER, Sylvia De Brakeleer

Publications

664

Citations

H-Index

Concepts

All Affiliations

Vrije Universiteit Brussel Universitair Ziekenhuis Brussel KU Leuven Université Libre de Bruxelles Molecular Oncology (United States)

About

Sylvia De Brakeleer is an author at Vrije Universiteit Brussel specializing in molecular diagnostics, pathology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	312
2	Cell Biology	2	2	164
3	Engineering	1	1	86
4	Microbiology	1	1	20
5	Molecular Biology	1	1	20

Sylvia De Brakeleer

Publications

589

Citations

H-Index

Page 1

	Year	Citations
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib Amir Noeparast, Erik Teugels, Philippe Giron, Oncotarget Braf Kinase ActivityImpaired Braf KinasesPathologyCancer BiologyTumor Biology	2016	100
De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes Erik Teugels, Sylvia De Brakeleer, Guido Goelen, Human Mutation	2005	99
Cancer predisposing missense and protein truncating<i>BARD1</i>mutations in non-<i>BRCA1</i>or<i>BRCA2</i>breast cancer families Sylvia De Brakeleer, Jacques De Grève, Remy Loris, Human Mutation EngineeringCancer PathologyGeneticsGenetic EpidemiologyPathology	2010	86
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab Shasha Lv, Erik Teugels, Jan Sadones, International Journal of Oncology Gene AmplificationPathologyHigh-grade GliomasRecurrent GlioblastomaGlioma	2012	64
Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families Rajendra Bahadur Shahi, Sylvia De Brakeleer, Ben Caljon, BMC Cancer	2019	49
The genomic landscape of nonsmall cell lung carcinoma in never smokers Bram Boeckx, Rajendra Bahadur Shahi, Dominiek Smeets, International Journal of Cancer Somatic VariantTumor HeterogeneityGenomic LandscapeGeneticsSmokers Signatures	2019	42
Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer Amir Noeparast, Philippe Giron, Sylvia De Brakeleer, Oncotarget	2018	31
Frequent incidence of <i><scp>BARD1</scp></i>‐truncating mutations in germline <scp>DNA</scp> from triple‐negative breast cancer patients Sylvia De Brakeleer, Jacques De Grève, Christine Desmedt, Clinical Genetics	2015	30
CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition Amir Noeparast, Philippe Giron, Alfiah Noor, Oncogene	2019	29
Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma. Lore Decoster, Isabelle Vande Broek, Bart Neyns, PubMed	2015	24

Page 1